A M Algotar1, R Behnejad2, P Singh3, P A Thompson4, C H Hsu5, S P Stratton2. 1. Department of Preventive Medicine, Loma Linda University Medical Center, Loma Linda, CA ; University of Arizona Cancer Center, Tucson, AZ. 2. University of Arizona Cancer Center, Tucson, AZ. 3. Department of Hematology-Oncology, University of Arizona, Tucson, AZ. 4. Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ. 5. Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ.
Abstract
OBJECTIVES: To determine the effect of selenium supplementation on the human proteomic profile. DESIGN: Serum samples were collected in this pilot study from a randomized placebo controlled Phase 2 clinical trial (Watchful Waiting (WW)). SETTING: Subjects were followed every three months for up to five years at the University of Arizona Prostate Cancer Prevention Program. PARTICIPANTS: One hundred and forty men (age < 85 years) had biopsy-proven prostate cancer, a Gleason sum score less than eight, no metastatic cancer, and no prior treatment for prostate cancer. INTERVENTION: As part of the WW trial, men were randomized to placebo, selenium 200 μg/day or selenium 800 μg/day. For the purpose of the current study, 40 subjects enrolled in the WW study (20 from the placebo group and 20 from Se 800 μg/day group) were selected. MEASUREMENTS: Baseline serum samples were collected at each follow-up visit and stored at -80 degrees Celsius. A multiplexed proteomic panel investigated changes in 120 proteins markers simultaneously. RESULTS:Thirteen proteins (Apolipoprotein J, IL-10, IL-1 alpha, MMP-3, IL-12p70, IL-2 receptor alpha, cathepsin B, eotaxin, EGFR, FGF-basic, myeloperoxidase, RANTES, TGF-beta) were determined to be either statistically (p-value < 0.05) or marginally significantly (0.05 < p-value <0.1) changed in the selenium supplemented group as compared to placebo. CONCLUSION: Although independent validation of these results is needed, this study is the first of its kind to utilize high throughput fluorescence based protein multiplex panel in analyzing changes in the proteomic profile due to selenium supplementation. Results from this study provide insight into the ability of selenium to modulate numerous protein markers and thus impact various biological processes in humans.
RCT Entities:
OBJECTIVES: To determine the effect of selenium supplementation on the human proteomic profile. DESIGN: Serum samples were collected in this pilot study from a randomized placebo controlled Phase 2 clinical trial (Watchful Waiting (WW)). SETTING: Subjects were followed every three months for up to five years at the University of Arizona Prostate Cancer Prevention Program. PARTICIPANTS: One hundred and forty men (age < 85 years) had biopsy-proven prostate cancer, a Gleason sum score less than eight, no metastatic cancer, and no prior treatment for prostate cancer. INTERVENTION: As part of the WW trial, men were randomized to placebo, selenium 200 μg/day or selenium 800 μg/day. For the purpose of the current study, 40 subjects enrolled in the WW study (20 from the placebo group and 20 from Se 800 μg/day group) were selected. MEASUREMENTS: Baseline serum samples were collected at each follow-up visit and stored at -80 degrees Celsius. A multiplexed proteomic panel investigated changes in 120 proteins markers simultaneously. RESULTS: Thirteen proteins (Apolipoprotein J, IL-10, IL-1 alpha, MMP-3, IL-12p70, IL-2 receptor alpha, cathepsin B, eotaxin, EGFR, FGF-basic, myeloperoxidase, RANTES, TGF-beta) were determined to be either statistically (p-value < 0.05) or marginally significantly (0.05 < p-value <0.1) changed in the selenium supplemented group as compared to placebo. CONCLUSION: Although independent validation of these results is needed, this study is the first of its kind to utilize high throughput fluorescence based protein multiplex panel in analyzing changes in the proteomic profile due to selenium supplementation. Results from this study provide insight into the ability of selenium to modulate numerous protein markers and thus impact various biological processes in humans.
Authors: Yasuhiko Makino; Donald N Cook; Oliver Smithies; Olivia Y Hwang; Eric G Neilson; Laurence A Turka; Hiroshi Sato; Andrew D Wells; Theodore M Danoff Journal: Clin Immunol Date: 2002-03 Impact factor: 3.969
Authors: Raghu Sinha; Indu Sinha; Nicole Facompre; Stephen Russell; Richard I Somiari; John P Richie; Karam El-Bayoumy Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07-19 Impact factor: 4.254
Authors: I C Gelissen; T Hochgrebe; M R Wilson; S B Easterbrook-Smith; W Jessup; R T Dean; A J Brown Journal: Biochem J Date: 1998-04-01 Impact factor: 3.857
Authors: M S Stratton; M E Reid; G Schwartzberg; F E Minter; B K Monroe; D S Alberts; J R Marshall; F R Ahmann Journal: Anticancer Drugs Date: 2003-09 Impact factor: 2.248
Authors: Robbie B Mailliard; Anna Wankowicz-Kalinska; Quan Cai; Amy Wesa; Catharien M Hilkens; Martien L Kapsenberg; John M Kirkwood; Walter J Storkus; Pawel Kalinski Journal: Cancer Res Date: 2004-09-01 Impact factor: 12.701
Authors: Dieuwertje E G Kok; Lambertus A L M Kiemeney; Gerald W Verhaegh; Jack A Schalken; Emile N J T van Lin; J P Michiel Sedelaar; J Alfred Witjes; Christina A Hulsbergen-van de Kaa; Pieter van 't Veer; Ellen Kampman; Lydia A Afman Journal: Oncotarget Date: 2017-02-07